Jasper Therapeutics (JSPR) Peer Comparison
$0.49
$-0.02
(-3.25%)
As on 03-Nov-2026 14:26EST
Market cap
$17 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
12.3
Div. Yield
0 %
Edit
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
17 | 14,600 | 11,611 | 11,755 | 8,769 |
Revenue ($ Mln) |
-- | 946 | 5,020 | 331,377 | 831 |
Net Profit ($ Mln) |
-31.77 | -570.21 | -199.00 | 28,032.40 | 54.90 |
Net Margin (%) |
-- | -60.30 | -3.96 | 8.46 | 6.61 |
RoE (%) |
-1,142.02 | -- | -3.03 | 7.51 | 8.11 |
Price to Earnings |
-- | -- | -- | 39.19 | 180.27 |
Price-To-Book |
12.31 | 123.68 | 1.72 | 2.91 | 12.42 |
Income Statement ($ Mln)
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 945.54 | 5,020.00 | 331,377.21 | 830.81 |
|
Cost of Revenue
|
0.31 | 61.34 | 2,380.00 | 167,448.74 | 14.09 |
|
Gross Profit
|
-1.06 | 473.81 | 2,050.00 | 190,428.00 | 748.43 |
|
Operating Expenses
|
55.14 | 1,294.12 | 2,178.00 | 134,367.32 | 810.32 |
|
Operating Profit (EBIT)
|
-55.16 | -409.91 | 462.00 | 29,561.14 | 6.41 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-31.77 | -578.95 | -166.00 | 35,270.62 | 26.37 |
|
Provision for Tax
|
0.00 | -4.96 | 33.00 | 7,639.53 | -35.26 |
|
Profit after Tax (Net Income)
|
-31.77 | -570.21 | -199.00 | 28,032.40 | 54.90 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 12,099.00 | 0.00 |
Liabilities ($ Mln)
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1.41 | -1,662.34 | 6,588.00 | 387,871.57 | 705.78 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Non-Current Liabilities
|
2.54 | 2,838.05 | 5,121.00 | 30,754.20 | 29.12 |
|
Current Liabilities
|
7.85 | 977.24 | 1,852.00 | 155,168.12 | 153.80 |
|
Total Liabilities
|
35.78 | 936.03 | 13,358.00 | 492,989.00 | 836.65 |
Assets ($ Mln)
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.23 | 117.18 | 9,764.00 | 278,119.64 | 449.03 |
|
Current Assets
|
11.57 | 2,044.61 | 3,797.00 | 298,879.23 | 439.68 |
|
Total Assets
|
35.78 | 936.03 | 13,358.00 | 492,989.00 | 836.65 |
|
Total Debt*
|
0.27 | 2,494.05 | 3,918.00 | 72,603.83 | 9.42 |
|
Net Current Assets
|
3.73 | 1,067.37 | 1,945.00 | 143,084.00 | 285.87 |
Cashflow ($ Mln)
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-77.16 | -445.91 | 560.00 | 46,428.00 | 142.00 |
|
Cash Flow from Investing Activities
|
0.01 | -24.49 | -279.00 | -58,077.00 | 69.76 |
|
Cash from Financing Activities
|
34.21 | 359.29 | -275.00 | 18,911.00 | -220.37 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-220.12 | -159.44 | -2.21 | 16.61 | 14.87 |
|
ROE (%)
|
-1,142.02 | 41.15 | -3.03 | 7.51 | 8.11 |
|
ROA (%)
|
-73.36 | -26.19 | -1.30 | 3.93 | 5.52 |
|
EBIT Margin (%)
|
-- | -47.10 | 1.61 | 9.79 | 3.17 |
|
Net Margin (%)
|
-- | -60.30 | -3.96 | 8.46 | 6.61 |
|
Cash Profit Margin (%)
|
-- | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 167.27 | 11.95 | -3.15 | 16.02 |
|
EBIT Growth (%)
|
65.06 | 34.77 | -90.61 | -59.13 | -79.11 |
|
Net Profit Growth (%)
|
65.06 | 28.47 | -145.85 | -52.18 | -58.66 |
|
EPS Growth (%)
|
73.74 | 30.63 | -146.42 | -52.16 | -62.44 |
|
Book Value Growth (%)
|
-96.79 | 16.42 | -3.87 | 8.16 | 12.98 |
Valuation Ratios
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.69 | -20.69 | -48.47 | 0.19 | 41.86 |
|
Price / Book Value
|
12.64 | -7.27 | 1.72 | 0.03 | 6.44 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.33 | -25.47 | 21.77 | 0.00 | 55.67 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.16 | 0.58 | 0.03 | 0.00 |
|
Short term debt to equity ratio
|
0.19 | -0.33 | 0.01 | 0.16 | 0.00 |
|
Current Ratio
|
1.47 | 2.09 | 2.05 | 1.93 | 2.86 |
|
Quick Ratio
|
1.47 | 2.03 | 1.10 | 1.40 | 2.77 |
|
Interest Coverage
|
-- | -3.33 | 0.36 | 8.78 | -- |
Operating Efficiency Ratios
| Jasper Therapeutics (JSPR) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 39.67 | 22.95 | 30.73 | 9.26 |
|
Asset Turnover
|
0.00 | 0.43 | 0.33 | 0.46 | 0.84 |
|
Receivable days
|
-- | 52.44 | 70.73 | 115.08 | 28.27 |
|
Inventory Days
|
-- | 172.81 | 226.89 | 181.99 | 355.76 |
|
Payable days
|
1,772.12 | 296.14 | 45.50 | 56.23 | 785.55 |
|
Cash Conversion Cycle
|
-- | -70.89 | 252.12 | 240.84 | -401.52 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
